Author

I. Mahmud

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:metabolomics· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

T. Garrett· 3 shared A. K. Sharma· 1 shared A. Raza· 1 shared A. Waddell· 1 shared B. K. Law· 1 shared B. Lee· 1 shared C. Chattopadhyay· 1 shared C. J. Stephenson· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

T. Garrett

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma

C. Chattopadhyay, J. Roszik, R. Bhattacharya, M. Alauddin, I. Mahmud, S. Yadugiri, M. M. Ali, F. S. Khan, V. V. Prabhu, P. Lorenzi, E. Burton, R. R. Morey, R. Lazcano, M. A. Davies, S. P. Patel, E. A. Grimm

The paper tests imipridones in a mouse model of uveal melanoma, finding they reduce tumor growth and improve survival by targeting oxidative phosphorylation.

bioRxiv · Jan 12, 2024Cancer Biology

Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A

S. Narayan, A. Raza, I. Mahmud, N. Koo, T. Garrett, M. E. Law, B. K. Law, A. K. Sharma

This study identifies NSC49L as a PP2A agonist that sensitizes FOLFOX-resistant colorectal cancer cells to TRAIL by downregulating the AKT1/mTOR/4EBP1-axis and p21 translation.

bioRxiv · Jul 21, 2021Cancer Biology

Niclosamide reverses SARS-CoV-2 control of lipophagy

T. Garrett, H. Coatsworth, I. Mahmud, T. Hamerly, C. J. Stephenson, H. Yazd, J. B. Ayers, M. Miller, J. A. Lednicky, R. R. Dinglasan

This study shows niclosamide reduces SARS-CoV-2 replication by modulating lipophagy and lipid metabolism in infected cells.

bioRxiv · Jul 11, 2021 · PreprintMicrobiology

The DAXX-SREBP axis promotes oncogenic lipogenesis and tumorigenesis

I. Mahmud, G. Tian, J. Wang, J. Lewis, A. Waddell, M. L. Lydon, L. Y. Zhao, J.-L. Li, H. T. Purayil, Z. Huo, Y. Daaka, T. J. Garrett, D. Liao

This study identifies the DAXX-SREBP axis as a driver of lipogenesis and tumorigenesis by showing its role in activating lipogenic gene expression and promoting tumor growth.

bioRxiv · Dec 31, 2020 · PreprintCancer Biology

Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery

B. Lee, I. Mahmud, J. Marchica, P. Derezinski, F. Qi, F. Wang, P. Joshi, F. Valerio, I. Rivera, V. Patel, C. P. Pavlovich, T. Garrett, G. P. Schroth, Y. Sun, R. J. Perera

The paper identifies urine-enriched RNAs and metabolites in prostate cancer patients and normal individuals, revealing altered glutamate metabolism and TCA cycle in cancer cells.

bioRxiv · Apr 4, 2019Cancer Biology